NO20056056L - N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer - Google Patents

N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer

Info

Publication number
NO20056056L
NO20056056L NO20056056A NO20056056A NO20056056L NO 20056056 L NO20056056 L NO 20056056L NO 20056056 A NO20056056 A NO 20056056A NO 20056056 A NO20056056 A NO 20056056A NO 20056056 L NO20056056 L NO 20056056L
Authority
NO
Norway
Prior art keywords
peroxisome proliferator
activated receptors
actyl
ligands
disease
Prior art date
Application number
NO20056056A
Other languages
English (en)
Inventor
Gary Michael Ksander
Thalaththani Ralalage Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20056056(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20056056L publication Critical patent/NO20056056L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) som er farmakologiske midler som binder til peroksisomproliferatoraktiviterte reseptorer, PPAR'er. I henhold til dette er forbindelsene ifølge oppfinnelsen nyttige ved behandling av tilstander som medieres av PPAR-reseptoraktiviteten i pattedyr. Slike tilstander inkluderer dyslipidemi, hyperlipidemi, aterosklerose, hypertriglyseridemi, hjertesvikt, myokardialt infarkt, vaskulære sykdommer, kardiovaskulære sykdommer, hypertensjon, obisitet, inflammasjon, artritt, cancer, Alzheimer's sykdom, hudforstyrrelser, respiratoriske sykdommer, oftalmiske forstyrrelser, inflammatoriske tarmsykdonimer (IIBD'er), ulcerativ kolitt, Crohn's sykdom, og tilstander hvori forringet glukosetoleranse, hyperglykemi og insulinresistens er inplikert, f.eks. type 1 - og type 2-diabetes og syndrom X.
NO20056056A 2003-05-20 2005-12-20 N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer NO20056056L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47206703P 2003-05-20 2003-05-20
PCT/EP2004/005434 WO2004103995A1 (en) 2003-05-20 2004-05-19 N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors

Publications (1)

Publication Number Publication Date
NO20056056L true NO20056056L (no) 2006-02-17

Family

ID=33476920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056056A NO20056056L (no) 2003-05-20 2005-12-20 N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer

Country Status (26)

Country Link
US (1) US7652061B2 (no)
EP (1) EP1638963B1 (no)
JP (1) JP4637843B2 (no)
KR (2) KR100849747B1 (no)
CN (1) CN1795193B (no)
AR (1) AR044399A1 (no)
AT (1) ATE442365T1 (no)
AU (1) AU2004240754B9 (no)
BR (1) BRPI0410779A (no)
CA (1) CA2525764C (no)
CL (1) CL2004001169A1 (no)
CO (1) CO5650248A2 (no)
DE (1) DE602004023080D1 (no)
EC (1) ECSP056175A (no)
ES (1) ES2331131T3 (no)
IS (1) IS8160A (no)
MA (1) MA27777A1 (no)
MX (1) MXPA05012465A (no)
NO (1) NO20056056L (no)
PE (1) PE20050157A1 (no)
PT (1) PT1638963E (no)
RU (1) RU2374241C2 (no)
TN (1) TNSN05295A1 (no)
TW (1) TW200524918A (no)
WO (1) WO2004103995A1 (no)
ZA (1) ZA200508905B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544784A (en) * 2003-07-28 2009-11-27 Reddys Lab Inc Dr Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
SG163518A1 (en) * 2004-06-24 2010-08-30 Incyte Corp Amido compounds and their use as pharmaceuticals
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
GT200500246A (es) * 2004-09-09 2006-04-17 Combinacion de compuestos organicos
ATE539743T1 (de) * 2005-06-27 2012-01-15 Newtree Co Ltd Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
EP2559455A1 (en) 2008-07-15 2013-02-20 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
JP5062097B2 (ja) * 2008-08-21 2012-10-31 富士通株式会社 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2625172B1 (en) 2010-10-07 2016-12-07 Novartis AG New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid
PT2663561E (pt) 2011-01-13 2016-06-07 Novartis Ag Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
MX2013008192A (es) 2011-01-13 2013-12-16 Novartis Ag Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
KR20140019834A (ko) 2011-04-14 2014-02-17 노파르티스 아게 글리코시드 유도체 및 그의 용도
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
CN103764635B (zh) 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CA2851445A1 (en) 2011-10-13 2013-04-18 Novartis Ag Novel oxazine derivatives and their use in the treatment of disease
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201406526WA (en) 2012-04-27 2014-11-27 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
WO2013163508A1 (en) 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
HRP20260171T1 (hr) 2017-12-14 2026-04-24 Université De Strasbourg Peptidi za liječenje i prevenciju bolesti nealkoholne masne jetre
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
AU2019408382B2 (en) 2018-12-21 2024-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides for treatment and prevention of diabetes and associated disorders
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
EP4476212A1 (en) 2022-02-10 2024-12-18 Novartis AG 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045540A (en) * 1990-05-25 1991-09-03 Warner-Lambert Co. Amino acid derivatives with angiotensin II antagonist properties
EP0915088B1 (en) * 1997-10-31 2002-09-18 F. Hoffmann-La Roche Ag D-Proline derivatives
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20060135593A1 (en) 2006-06-22
PE20050157A1 (es) 2005-05-17
ES2331131T3 (es) 2009-12-22
CN1795193A (zh) 2006-06-28
CL2004001169A1 (es) 2005-03-28
JP2007501263A (ja) 2007-01-25
JP4637843B2 (ja) 2011-02-23
WO2004103995A1 (en) 2004-12-02
ECSP056175A (es) 2006-04-19
EP1638963A1 (en) 2006-03-29
BRPI0410779A (pt) 2006-06-27
TW200524918A (en) 2005-08-01
MXPA05012465A (es) 2006-01-30
CA2525764A1 (en) 2004-12-02
KR100849747B1 (ko) 2008-07-31
AR044399A1 (es) 2005-09-14
CA2525764C (en) 2012-07-17
EP1638963B1 (en) 2009-09-09
DE602004023080D1 (de) 2009-10-22
ZA200508905B (en) 2008-08-27
KR100909918B1 (ko) 2009-07-29
MA27777A1 (fr) 2006-02-01
KR20060014054A (ko) 2006-02-14
KR20080007519A (ko) 2008-01-21
RU2374241C2 (ru) 2009-11-27
CN1795193B (zh) 2010-08-18
RU2005139525A (ru) 2006-08-10
ATE442365T1 (de) 2009-09-15
PT1638963E (pt) 2009-11-18
CO5650248A2 (es) 2006-06-30
AU2004240754B9 (en) 2008-10-23
IS8160A (is) 2005-11-30
TNSN05295A1 (en) 2007-07-10
AU2004240754A1 (en) 2004-12-02
US7652061B2 (en) 2010-01-26
AU2004240754B2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
NO20056056L (no) N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer
ECSP045103A (es) Compuestos heterociclicos y metodos de uso
BRPI0412380A (pt) compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
MXPA06003055A (es) Compuestos organicos.
ATE386715T1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
RU2010120808A (ru) Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
PH12016502294A1 (en) Novel fatty acids and their use in conjugation to biomolecules
NZ715983A (en) Vasoprotective and cardioprotective antidiabetic therapy
JP2006527210A (ja) ホルモン感受性リパーゼ阻害剤としてのピリジニルカルバメート
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
MA30201B1 (fr) Derives triazoliques comme inhibiteurs de la 11-beta-hydroxysteroide dehydrogenase-1
AR047669A1 (es) Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
WO2004037248A3 (en) Modulation of peroxisome proliferator activated receptors activity
MY148434A (en) Fused bicyclic heteroaryl derivatives
WO2005115383A3 (en) Substituted triazoles as modulators of ppar and methods of their preparation
JP2008532974A5 (no)
JP2007537289A5 (no)
BR0318685A (pt) compostos de cetona e composições para controle de colesterol e usos relacionados
RU2012113924A (ru) 5-(3,4-дихлорфенил)-n-(2-гидроксициклогексил)-6-(2,2,2-трифторэтокси)никотинамид и его соли в качестве средств, повышающих концентрацию лвп холестерина
NO20055307L (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
BR0315683A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento e/ou prevenção de condições mediadas por receptores nucleares e para o tratamento e/ou prevenção do diabete do tipo i, diabete do tipo ii, tolerância à glicose prejudicada, resistência à insulina ou obesidade
WO2005115384A3 (en) Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application